Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Small Cell Lung Cancer, Uveal Melanoma, Ovarian Clear Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancies, Solid Tumor, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
Interventions: PLX2853; Drug
Lead sponsor: Opna Bio LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Scottsdale, Arizona • Miami, Florida • New York, New York + 2 more

Conditions: Cardiac Arrhythmia, Atrial Fibrillation
Interventions: Quality improvement; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Skin Graft
Interventions: 10% PEP, TISSEEL, 20% PEP; Biological · Drug
Lead sponsor: Rion Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Doral, Florida • Rochester, Minnesota

Conditions: Transcatheter Aortic Valve Replacement, Closure Technique
Interventions: Double Perclose Proglide, Single Perclose Proglide plus Angioseal; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions: Microdevice; Combination Product
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pregnancy
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Nutrition, Health, Dietary Habits
Interventions: Diet A, Diet B, Diet C; Other
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 7 more

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND); Biological · Other · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more

Conditions: Androgenetic Alopecia
Interventions: KX0826, Placebo; Drug · Other
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Interventions: Everolimus, Paclitaxel; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more

Conditions: Acne Vulgaris
Interventions: Red Light (PDT); Drug
Lead sponsor: Dermira, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
Interventions: CTX-8371; Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Palo Alto, California • Margate, Florida + 8 more

Conditions: Hemorrhagic Fever, Ebola
Interventions: Ad26.ZEBOV, MVA-BN-Filo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 0 Years to 71 Years
Enrollment: 677 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Effects of Chemotherapy, Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 11 Years to 35 Years · Female only
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 42
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more

Conditions: Primary Liver Cancer, Metastatic Liver Cancer From Any Cancer Site
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions: Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ); Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 25 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • Seattle, Washington

Conditions: Healthy Participants
Interventions: PMN310, Placebo; Drug
Lead sponsor: ProMis Neurosciences, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Miami, Florida • Columbus, Ohio

Conditions: Metastatic Colorectal Cancer
Interventions: Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
Interventions: Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil; Drug · Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 65 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Subjects
Interventions: ALXN1007; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Kidney Metabolic Syndrome
Interventions: Intervention, Active Comparator; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 23,280,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cardiac Pacing
Interventions: Cardiac Waveform Generator; Device
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
Interventions: LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Miami, Florida • Detroit, Michigan • New York, New York + 1 more

Search by objective public record fields.

A Study of PLX2853 in Advanced Malignancies.

Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient Management From the ER

PEP on a Skin Graft Donor Site Wound

This Study Will Evaluate the Safety and Potential Complications of Dual ProGlide vs Single ProGlide and Angioseal for Common Femoral Arteriotomy Closure Following Transcatheter Aortic Valve Replacement

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project

Nutrition for Precision Health, Powered by the All of Us

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Ovarian Reserve After Cancer: Longitudinal Effects

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

A Phase 1a Study of PMN310 In Healthy Volunteers

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

Cardiac Anodal Biphasic Pacing

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors